Guggenheim Starts Orchard Therapeutics (ORTX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ORTX Hot Sheet
Price: $16.70 --0%
Rating Summary:
6 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
6 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Guggenheim analyst Whitney Ljem initiates coverage on Orchard Therapeutics (NASDAQ: ORTX) with a Buy rating and a price target of $31.00.
For an analyst ratings summary and ratings history on Orchard Therapeutics click here. For more ratings news on Orchard Therapeutics click here.
Shares of Orchard Therapeutics closed at $15.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Guggenheim Starts Lockheed Martin (LMT) at Buy
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- Morgan Stanley Starts Elevate Campuses Ltd (ELEVATE:IN) at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
